Neoplasms

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Rare Diseases

Carcinoma

Adenocarcinoma

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Cystadenocarcinoma, Serous

Fallopian Tube Neoplasms

Ovarian Diseases

Cystadenocarcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Endocrine Gland Neoplasms

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Urogenital Neoplasms

Endocrine System Diseases

Gonadal Disorders

Neoplasms, Cystic, Mucinous, and Serous

Fallopian Tube Diseases

Ovarian Cancer

Ovarian Epithelial Cancer

Adenocarcinoma of the Appendix

200 participants scheduled for surgery for suspected ovarian cancer due to a pelvic mass but without a confirmed tissue or cytology diagnosis.

50 participants with an inherited BRCA1 or BRCA2 deleterious mutation without suspected ovarian cancers who are scheduled for risk-reducing salpingo-oophorectomy (RRSO) to remove ovaries and fallopian tubes.

Uterine lavage is performed during surgery using a flexible, 3-way balloon tipped catheter. The catheter is inserted through the cervix, the balloon expanded and the uterine cavity lavaged using 10 cc of sterile saline which is collected, processed and stored for later analysis.

Uterine lavage, or a wash of the womb

Participants undergo two blood draws (one required, one optional) up to 31 days before surgery

Blood sample

Participants undergo a standard Papanicolaou smear to collect cells and fluid from the cervix.

Pap smear

Jackie Dahlgren

Beth Scanlan

Kristin Zorn, MD

Isabel Perez

Christine Garcia, MD

Jaci Miller

Monica Jones, MD

Rebecca Stone, MD

Tina Colella

Amy Bregar, MD

Robert Pearhill

Charles Drescher, MD

Christos Patriotis, PhD

The study aims to develop a test for early detection of ovarian cancer using DNA from a growth involving the ovary found in a washing of the uterus (womb), and proteins found in the blood. The samples of the wash and the blood will be taken before surgery. After surgery, doctors will determine whether the participant had ovarian cancer or a benign disease of the ovaries. The tests of the washings and the blood will be examined to see how much the participants with ovarian cancer can be separated from the participants with a benign ovarian disease by the tests. Small amounts from the washing and the blood samples will be sent to four sites for analysis.

Statistical analyses of these data will compare tumor DNA found in the washing of the uterus with proteins in the blood to detect cases of ovarian cancer. The primary goal is to find tests that are mostly positive for cases of ovarian cancer and mostly negative for patients with benign disease. It is hoped that if the tests work for participants with symptoms of the disease that these tests will also work when testing women who have no symptoms. A new study would be needed to see if the tests worked in this situation. If the tests work, this could lead to increasing the number of cases detected in early stage disease and decreasing the number of cases detected in late stage disease. If this change in late stage is large, it will likely reduce deaths due to ovarian cancer.

The study aims to elucidate the relative contributions to detection of ovarian cancer from tumor DNA in uterine lavage (UL) and protein biomarkers from blood using newly available detection and sample collection technologies. In this document, the term "ovarian cancer" includes fallopian tube cancer. In the first cohort, the study will enroll 200 participants. Enrolling participants prior to surgical diagnosis (e.g. laparoscopy or paracentesis) ensures the study will be "Prospective Collection of Samples, Blinded Evaluation" (PRoBE) compliant. The expectation is that \~50 of these participants will have pathologically confirmed ovarian cancer. In a second cohort, 50 participants will be enrolled. Based on published reports, it is expected that \~5 participants will have microscopic or low volume ovarian cancer. In each cohort, the participants with a pathologic invasive epithelial ovarian cancer diagnosis will be defined as Cases and participants without any ovarian cancer, primary peritoneal cancer (PPC), or other cancer identified due to the surgery, will be defined as Controls. Other cancer groups are: (i) PPC, (ii) non-invasive serous tubal intraepithelial carcinoma (STIC) lesions, (iii) non-epithelial ovarian cancers, and (iv) non-ovarian cancers.

Two sites will sequence DNA obtained from uterine lavages to detect tumor-derived DNA (tDNA): one will carry out Duplex Sequencing of TP53 and the second site will carry out Haloplex sequencing of an 18-gene panel. Two other sites will assay serum proteins: the first will use clinical grade assays for CA125 and HE4, and the second will use research grade assays for these two proteins plus four additional protein biomarker candidates. Statistical analyses of these data will evaluate the relative utility of tDNA and plasma proteins to detect Cases (sensitivity) while limiting detection of Controls (specificity) in these two cohorts. Remaining DNA from UL and blood based biospecimens in form of plasma, serum, and buffy coat will be stored at a biorepository at NCI Frederick for future biomarker investigations which include (but are not limited to) other methods of detecting tDNA from UL, tDNA from plasma, exosomal markers, and additional blood-based and UL biomarker candidates.

Primary objectives:

1. To collect samples from 200 participants with suspected ovarian cancer (of which \~50 or more are expected to have pathologically confirmed ovarian cancer) and 50 participants undergoing a risk-reducing salpingo-oophorectomy (of which \~5 are expected to have microscopic or low volume ovarian cancer).
2. To test the tDNA from uterine lavage samples for tumor-derived TP53 mutations, using Duplex sequencing, and for potential abnormalities in an 18-gene panel, using Haloplex sequencing
3. To test the serum proteins with two assays: the first will use clinical grade assays for CA125 and HE4, and the second will use research grade assays for these two proteins plus four additional protein biomarker candidates.

Outline: Participants undergo two blood draws (one required, one optional) up to 31 days before surgery and a uterine lavage at the time of planned surgery. The tDNA and serum proteins are then extracted from the samples and sent for analysis.

* Serum (red-top tubes)
* EDTA plasma (purple-top tubes)
* Uterine Lavage supernatant (conical tube)
* Uterine Lavage filter (conical tube)
* Uterine Lavage cell pellet (conical tube)
* Buffy coat (purple-top tubes)
* Tissue sections

Developing a Test for the Detection of Ovarian Cancer

Ovarian Cancer Detection by Uterine Lavage DNA and Serum Proteins: a Phase 2 Biomarker Study

Individual participant data is not anticipated to be shared.

Biomarkers that distinguish between ovarian cancer and benign ovarian disease

Johns Hopkins University

Fred Hutchinson Cancer Center

Anne Arundel Health System Research Institute

University of Arkansas

National Cancer Institute (NCI)

Kaiser Permanente

McGill University

M.D. Anderson Cancer Center

Swedish Medical Center

TwinStrand Biosciences

Massachusetts General Hospital

Principal Investigator

Digestive System Diseases

Symptoms and General Pathology

Carcinoma, Hepatocellular

Neuroendocrine Tumors

Neoplastic Cells, Circulating

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms, Nerve Tissue

Neoplasm Metastasis

Neoplastic Processes

Liver Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

Neuroendocrine Tumor

Neuroepithelioma

Antineoplastic Agents

All Drugs and Chemicals

Gastrointestinal Agents

Anti-Infective Agents

Everolimus

Somatostatin

Octreotide

Sorafenib

Lanreotide

Sirolimus

Temsirolimus

MTOR Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Immunosuppressive Agents

Immunologic Factors

Antineoplastic Agents, Hormonal

HCC patients referred for Sorafenib treatment

HCC patient undergoing potential curative treatment, eg. radiofrequency ablation (RFA) or resection

Pancreatic NET patients referred for Everolimus treatment

Small intestinal or unknown primary NET patients referred for treatment with somatostatin analogues, eg. lanreotide and octreotide

Radiofrequency ablation (RFA) or surgery

Or other somatostatin analogues (SSTA), eg. Sandostatin

Jens Kelsen, Consultant

Background Treatment and control of cancer is associated with high costs, to patients in the form of side effects and discomfort during investigations, to society in the form of expensive drugs and studies.

Circulating tumor cells (CTC) has received great attention as a cancer biomarker in trying to estimate future course in patients with breast cancer, colon cancer and prostate cancer. CTC is believed to be a crucial step in cancer spreading to the bloodstream and giving rise to metastases. Detection of circulating tumor DNA (ctDNA) specifically adds specificity to the analysis of the CTC.

The investigators would like to with molecular biological methods predict which patients requires special monitoring and individualized therapy and explore these tests as clinical decision support.

Purpose and method

In a blood sample from patients with neuro-endocrine tumor (NET) and hepatocellular carcinoma (HCC), the investigators will by cell separation, flow cytometry and DNA sequencing and digital polymerase chain reaction (PCR):

1. Identify and isolate the CTC and investigate these for tumor-specific mutations.
2. Quantify ctDNA and analyze this for specific mutations, which in the past has been found frequent in NET and HCC.
3. Compare findings of mutations on CTC and ctDNA with mutations in tissue biopsies.

The results are compared with the clinical data on disease course, including the effect of treatment and survival.

Subjects 40 Patients with small intestinal/unknown primary NET before treatment with somatostatin analogues 30 patients with pancreatic NET before treatment with Everolimus 30 patients with presumed radically treated HCC 30 patients with HCC in treatment with Sorafenib A blood sample will be taken prior to the start of treatment, after 1 month after start of treatment and thereafter every 3.-6. month for up to two years.

Perspectives In several cancer types molecular diagnostics have had significant influence in treatment and control strategy. The goal is in future to be able to take advantage of a so-called "liquid biopsy" as clinical decision support. The study will bring new knowledge to this growing field of research.

Blood samples and biopsies when available.

Circulating Tumor Cells and Tumor DNA in HCC and NET

Circulating Tumor Cells and Tumor DNA in HCC and NET - Patient-specific Biomarkers for Clinical Decision Support and Tailored Relapse Diagnostics

Methods: digital droplet PCR and targeted sequencing of blood samples and biopsies

Methods: digital droplet PCR and targeted sequencing of blood samples, and flowcytometry and cell separation of blood samples

Aarhus University Hospital

University of Aarhus

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Developing a Test for the Detection of Ovarian Cancer	NCT04794322	Ovarian Neoplas... Ovarian Epithel... Fallopian Tube ... High Grade Ovar... Stage I Ovarian... Stage II Ovaria... Stage III Ovari... Stage IIIA Ovar... Stage IIIA1 Ova... Stage IIIA2 Ova... Stage IIIB Ovar... Stage IIIC Ovar... Stage IV Ovaria... Stage IVA Ovari... Stage IVB Ovari...	Uterine lavage,... Blood sample Pap smear	30 Years -	Massachusetts General Hospital
Developing a Test for the Detection of Ovarian Cancer	NCT04794322	Ovarian Neoplas... Ovarian Epithel... Fallopian Tube ... High Grade Ovar... Stage I Ovarian... Stage II Ovaria... Stage III Ovari... Stage IIIA Ovar... Stage IIIA1 Ova... Stage IIIA2 Ova... Stage IIIB Ovar... Stage IIIC Ovar... Stage IV Ovaria... Stage IVA Ovari... Stage IVB Ovari...	Uterine lavage,... Blood sample Pap smear	30 Years -	Massachusetts General Hospital
Circulating Tumor Cells and Tumor DNA in HCC and NET	NCT02973204	Carcinoma, Hepa... Neuroendocrine ...	Sorafenib Radiofrequency ... Everolimus Lanreotide	18 Years -	University of Aarhus
Circulating Tumor Cells and Tumor DNA in HCC and NET	NCT02973204	Carcinoma, Hepa... Neuroendocrine ...	Sorafenib Radiofrequency ... Everolimus Lanreotide	18 Years -	University of Aarhus
Circulating Tumor Cells and Tumor DNA in HCC and NET	NCT02973204	Carcinoma, Hepa... Neuroendocrine ...	Sorafenib Radiofrequency ... Everolimus Lanreotide	18 Years -	University of Aarhus

Spots Global Cancer Trial Database for tumor dna

Every month we try and update this database with for tumor dna cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for tumor dna

Every month we try and update this database with for tumor dna cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for tumor dna cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.